Local bullous reaction as a cutaneous reaction after mRNA‐boosted vaccination in a post‐COVID patient

Abstract

Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The spectrum of symptomatic infection ranges from mild to critical with multiple severe complications. Many vaccines have been developed to prevent COVID‐19 disease, including an mRNA vaccine. Different adverse effects were reported as delayed large local reactions, swelling, erythema, urticarial, and morbilliform rashes. Among these, bullous reactions from the vaccine are considered rare. Here, we described a local bullous reaction after an mRNA booster vaccination in a post‐COVID patient.

The pathophysiology and clinical phenotypes of COVID-19 mRNA vaccine-related cutaneous adverse reactions: A narrative review

“…DLLR is clinically characterized by indurated erythema extending widely from the injection site and accompanies tenderness and itching, and sometimes by vesicles and/or blister [42][43][44] . It is of note that DLLR sometimes coexists with generalized or localized eruption apart from injection site (Figure 2).…”